BioCentury | Oct 15, 2012
Company News

Escalon Medical, Erba Diagnostics deal

...June 30, Escalon had $890,623 in cash and a 12-month operating loss of $2.2 million. Escalon Medical Corp....
BioCentury | Jan 25, 1999
Clinical News

Ocufit SR: Phase I trials update

...eye over several weeks Indication: Treat post-operative inflammation after cataract surgery Status: West and partner Escalon Medical Corp....
BioCentury | Mar 30, 1998
Finance

GeneMedicine Inc. (GMED)

...activity would increase the market price" of the gene therapy company and two non-biotech stocks, Escalon Medical Corp....
Items per page:
1 - 3 of 3
BioCentury | Oct 15, 2012
Company News

Escalon Medical, Erba Diagnostics deal

...June 30, Escalon had $890,623 in cash and a 12-month operating loss of $2.2 million. Escalon Medical Corp....
BioCentury | Jan 25, 1999
Clinical News

Ocufit SR: Phase I trials update

...eye over several weeks Indication: Treat post-operative inflammation after cataract surgery Status: West and partner Escalon Medical Corp....
BioCentury | Mar 30, 1998
Finance

GeneMedicine Inc. (GMED)

...activity would increase the market price" of the gene therapy company and two non-biotech stocks, Escalon Medical Corp....
Items per page:
1 - 3 of 3